140 related articles for article (PubMed ID: 33593688)
1. Estimation of manufacturing development costs of cell-based therapies: a feasibility study.
Ten Ham RMT; Nievaart JC; Hoekman J; Cooper RS; Frederix GWJ; Leufkens HGM; Klungel OH; Ovelgönne H; Hoefnagel MHN; Turner ML; Mountford JC
Cytotherapy; 2021 Aug; 23(8):730-739. PubMed ID: 33593688
[TBL] [Abstract][Full Text] [Related]
2. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
3. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
4. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
5. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
6. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
7. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.
Wilkie GM; Taylor C; Jones MM; Burns DM; Turner M; Kilpatrick D; Amlot PL; Crawford DH; Haque T
J Immunother; 2004; 27(4):309-16. PubMed ID: 15235392
[TBL] [Abstract][Full Text] [Related]
9. A roadmap for cost-of-goods planning to guide economic production of cell therapy products.
Lipsitz YY; Milligan WD; Fitzpatrick I; Stalmeijer E; Farid SS; Tan KY; Smith D; Perry R; Carmen J; Chen A; Mooney C; Fink J
Cytotherapy; 2017 Dec; 19(12):1383-1391. PubMed ID: 28935190
[TBL] [Abstract][Full Text] [Related]
10. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.
Gallot G; Vollant S; Saïagh S; Clémenceau B; Vivien R; Cerato E; Bignon JD; Ferrand C; Jaccard A; Vigouroux S; Choquet S; Dalle JH; Frachon I; Bruno B; Mothy M; Mechinaud F; Leblond V; Milpied N; Vié H
J Immunother; 2014 Apr; 37(3):170-9. PubMed ID: 24598452
[TBL] [Abstract][Full Text] [Related]
11. Bringing Stem Cell-Based Therapies for Type 1 Diabetes to the Clinic: Early Insights from Bioprocess Economics and Cost-Effectiveness Analysis.
Bandeiras C; Cabral JMS; Gabbay RA; Finkelstein SN; Ferreira FC
Biotechnol J; 2019 Aug; 14(8):e1800563. PubMed ID: 31127682
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study using time-driven activity-based costing as a management tool for provider cost estimation: lessons from the national TB control program in Zimbabwe in 2018.
Chirenda J; Nhlema Simwaka B; Sandy C; Bodnar K; Corbin S; Desai P; Mapako T; Shamu S; Timire C; Antonio E; Makone A; Birikorang A; Mapuranga T; Ngwenya M; Masunda T; Dube M; Wandwalo E; Morrison L; Kaplan R
BMC Health Serv Res; 2021 Mar; 21(1):242. PubMed ID: 33736629
[TBL] [Abstract][Full Text] [Related]
13. A time-driven activity-based costing model to improve health-care resource use in Mirebalais, Haiti.
Mandigo M; O'Neill K; Mistry B; Mundy B; Millien C; Nazaire Y; Damuse R; Pierre C; Mugunga JC; Gillies R; Lucien F; Bertrand K; Luo E; Costas A; Greenberg SL; Meara JG; Kaplan R
Lancet; 2015 Apr; 385 Suppl 2():S22. PubMed ID: 26313069
[TBL] [Abstract][Full Text] [Related]
14. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
16. [iPSC-derived rejuvenated T-cell therapy for Epstein-Barr virus-associated lymphomas].
Ando M; Nakauchi H; Komatsu N
Rinsho Ketsueki; 2018; 59(7):932-938. PubMed ID: 30078805
[TBL] [Abstract][Full Text] [Related]
17. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
18. Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows.
Verbarendse M; Snyder R; Lakshmipathy U
Cytotherapy; 2023 Oct; 25(10):1107-1112. PubMed ID: 37294247
[TBL] [Abstract][Full Text] [Related]
19. The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4
Adhikary D; Damaschke J; Mautner J; Behrends U
J Virol; 2020 Jul; 94(15):. PubMed ID: 32461311
[TBL] [Abstract][Full Text] [Related]
20. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
